EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

ZNF251 haploinsufficiency confers PARP inhibitors resistance in BRCA1-mutated cancer cells through activation of homologous recombination

Huan Li, Srinivas Chatla, Xiaolei Liu, Zhen Tian, Umeshkumar Vekariya, Peng Wang, Dongwook Kim, Stacia Octaviani, Zhaorui Lian, George Morton, Zijie Feng, Dan Yang und 7 weitere

Cancer Letters · 2025

DOI: 10.1016/j.canlet.2025.217505 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Letters, 2025. Verfasst von Huan Li und 18 weiteren Autor:innen. Beteiligte Einrichtung: Coriell Institute for Medical Research, Camden, NJ, United States. Hauptthemen laut MEDLINE: Poly(ADP-ribose) Polymerase Inhibitors, Drug Resistance, Neoplasm, BRCA1 Protein, Haploinsufficiency. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Poly (ADP-ribose) polymerase inhibitors (PARPis) represent a promising new class of agents that have demonstrated efficacy in treating various cancers, particularly those with BRCA1/2 mutations. Cancer-associated BRCA1/2 mutations disrupt DNA double-strand break (DSB) repair via homologous recombination (HR). PARP inhibitors (PARPis) have been used to trigger synthetic lethality in BRCA1/2-mutated cancer cells by promoting the accumulation of toxic DSBs. Unfortunately, resistance to PARPis is common and can occur through multiple mechanisms, including the restoration of HR and/or stabilization of replication forks. To gain a better understanding of the mechanisms underlying PARPis resistance, we conducted an unbiased CRISPR-pooled genome-wide library screen to identify new genes whose deficiency confers resistance to the PARPi olaparib. Our research revealed that haploinsufficiency of the ZNF251 gene, which encodes zinc finger protein 251, is associated with resistance to PARPis in various breast and ovarian cancer cell lines carrying BRCA1 mutations. Mechanistically, we discovered that ZNF251 haploinsufficiency leads to stimulation of RAD51-mediated HR repair of DSBs in olaparib-treated BRCA1-mutated cancer cells. Moreover, we demonstrated that a RAD51 inhibitor reversed PARPi resistance in ZNF251 haploinsufficient cancer cells harboring BRCA1 mutations. Our findings provide important insights into the mechanisms underlying PARPis resistance by highlighting the role of RAD51 in this phenomenon.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Poly(ADP-ribose) Polymerase InhibitorsDrug Resistance, NeoplasmBRCA1 ProteinHaploinsufficiencyHomologous RecombinationBreast NeoplasmsOvarian NeoplasmsHumansCell Line, TumorPhthalazinesPiperazinesFemaleMutationRad51 RecombinaseDNA Breaks, Double-Stranded

Substanzen

Poly(ADP-ribose) Polymerase InhibitorsBRCA1 ProteinolaparibBRCA1 protein, humanPhthalazinesPiperazinesRad51 RecombinaseRAD51 protein, human

Autor:innen und Institutionen

  • Coriell Institute for Medical Research, Camden, NJ, United States.
  • Fels Cancer Institute for Personalized Medicine, Temple University Lewis Katz School of Medicine, Philadelphia, PA, United States.
  • Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, United States.
  • Moulder Center for Drug Discovery Research, School of Pharmacy, Department of Pharmaceutical Sciences, Temple University, Philadelphia, PA, United States.
  • Department of Cancer Biology, Abramson Family Cancer Research Institute, Institute of Diabetes, Obesity, and Metabolism, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, United States.
  • Shanghai Jiao Tong University, School of Life Science and Biotechnology, Shanghai, PR China.

Zitieren

APA

Li, H., Chatla, S., Liu, X., Tian, Z., Vekariya, U., Wang, P., Kim, D., Octaviani, S., Lian, Z., Morton, G., Feng, Z., Yang, D., Sullivan-Reed, K., Childers, W., Yu, X., Chitrala, K. N., Madzo, J., Skorski, T., & Huang, J. (2025). ZNF251 haploinsufficiency confers PARP inhibitors resistance in BRCA1-mutated cancer cells through activation of homologous recombination. Cancer Letters. https://doi.org/10.1016/j.canlet.2025.217505

Vancouver

Li H, Chatla S, Liu X, Tian Z, Vekariya U, Wang P, et al. ZNF251 haploinsufficiency confers PARP inhibitors resistance in BRCA1-mutated cancer cells through activation of homologous recombination. Cancer Letters. 2025. doi:10.1016/j.canlet.2025.217505

BibTeX
@article{Li2025,
  author = {Li, Huan and Chatla, Srinivas and Liu, Xiaolei and Tian, Zhen and Vekariya, Umeshkumar and Wang, Peng and Kim, Dongwook and Octaviani, Stacia and Lian, Zhaorui and Morton, George and Feng, Zijie and Yang, Dan and Sullivan-Reed, Katherine and Childers, Wayne and Yu, Xiang and Chitrala, Kumaraswamy Naidu and Madzo, Jozef and Skorski, Tomasz and Huang, Jian},
  title = {ZNF251 haploinsufficiency confers PARP inhibitors resistance in BRCA1-mutated cancer cells through activation of homologous recombination},
  journal = {Cancer Letters},
  year = {2025},
  doi = {10.1016/j.canlet.2025.217505}
}
Kostenlos starten →